On the basis of our findings, additional inhibitors that protect endothelial barrier function by activating Rac1 and TSCs or indirectly impact Rac1/RhoA also have the potential to inhibit capillary leakage and therapeutically resolve or reduce HPS disease. This evidence concerns the gene RAC1 and Hermansky-Pudlak syndrome.